Other Health

IWBI Announces New Co-chairs and More than 225 Members of the Task Force on COVID-19 and Other Respiratory Infections: Prevention and Preparedness, Resilience and Recovery

Monday, April 6, 2020 - 10:03pm

We have been truly overwhelmed by the passionate response of our global community to raise their hands and get involved in the Task Force on COVID-19, said IWBI Chairman and CEO Rick Fedrizzi.

Key Points: 
  • We have been truly overwhelmed by the passionate response of our global community to raise their hands and get involved in the Task Force on COVID-19, said IWBI Chairman and CEO Rick Fedrizzi.
  • This Task Force provides a mechanism to focus on this immediate challenge and collect and apply the expertise and insight of hundreds of leaders from their respective fields.
  • Gutter noted that the importance of moving quickly to translate actionable strategies into practice isnt lost on this group.
  • The International WELL Building Institute (IWBI) is leading the global movement to transform our buildings, communities and organizations in ways that help people thrive.

BELLUS Health Announces Completion of Dosing in Phase 2 RELIEF Trial with BLU-5937 for the Treatment of Refractory Chronic Cough

Monday, April 6, 2020 - 10:00pm

The Company decided to close the trial early due to the impact of the COVID-19 pandemic on the RELIEF clinical trial activities.

Key Points: 
  • The Company decided to close the trial early due to the impact of the COVID-19 pandemic on the RELIEF clinical trial activities.
  • A total of 68 patients with refractory chronic cough were enrolled into the trial, with 52 completing treatment.
  • With 52 patients completing dosing, the RELIEF trial is the largest crossover study conducted in refractory chronic cough, providing the powering needed to evaluate efficacy and safety of BLU-5937, said Roberto Bellini, President and CEO of BELLUS Health.
  • BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders.

NanoString Provides COVID-19 Business Update and Announces Conference Call on Thursday May 7th, 2020

Monday, April 6, 2020 - 9:01pm

Our recently completed $230 million financing provides a strong balance sheet that will support the Company while we navigate this period of uncertainty.

Key Points: 
  • Our recently completed $230 million financing provides a strong balance sheet that will support the Company while we navigate this period of uncertainty.
  • Company management will host a conference call beginning at 4:30pm ET to discuss those results and provide a business update.
  • NanoString, NanoString Technologies, the NanoString logo, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.
  • You should read our unaudited consolidated financial statements for the three months ended March 31, 2020 once they become available.

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Monday, April 6, 2020 - 9:15pm

The options were granted as inducement equity awards outside of the Companys 2013 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4), and were made as an inducement material to the acceptance of employment with the Company by each of the new employees.

Key Points: 
  • The options were granted as inducement equity awards outside of the Companys 2013 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4), and were made as an inducement material to the acceptance of employment with the Company by each of the new employees.
  • The options are subject to the terms and conditions of stock option agreements covering the respective grants and the GlycoMimetics, Inc. Inducement Plan, which was adopted January 22, 2020 and provides for the granting of stock options to new employees.
  • The stock option awards have an exercise price equal to the closing price of the Companys common stock on April 1, 2020.
  • GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist.

Ralph Lauren Corporation Provides Business Update on COVID-19

Monday, April 6, 2020 - 9:30pm

Ralph Lauren Corporation (NYSE: RL) today shared details regarding the additional steps the Company is taking to navigate the impacts of COVID-19.

Key Points: 
  • Ralph Lauren Corporation (NYSE: RL) today shared details regarding the additional steps the Company is taking to navigate the impacts of COVID-19.
  • The impact of COVID-19 on the world, on our industry and on our business is profound and wide-reaching, said Ralph Lauren, Executive Chairman & Chief Creative Officer.
  • Ralph Lauren Corporation (NYSE:RL) is a global leader in the design, marketing and distribution of premium lifestyle products in five categories: apparel, footwear & accessories, home, fragrances and hospitality.
  • The Companys brand names, which include Ralph Lauren, Ralph Lauren Collection, Ralph Lauren Purple Label, Polo Ralph Lauren, Double RL, Lauren Ralph Lauren, Polo Ralph Lauren Children, Chaps and Club Monaco, among others, constitute one of the worlds most widely recognized families of consumer brands.

EKIMAS Corporation Announces Special Cash Distribution

Monday, April 6, 2020 - 6:51pm

EKIMAS Corporation (OTCQB: ASNB), formerly AdvanSource Biomaterials Corporation (the Company), which sold substantially all of its assets to Mitsubishi Chemical Performance Polymers, Inc. on January 31, 2020, today announced that the Companys Board of Directors approved a special cash distribution of $0.18 per share at its April 3, 2020 meeting.

Key Points: 
  • EKIMAS Corporation (OTCQB: ASNB), formerly AdvanSource Biomaterials Corporation (the Company), which sold substantially all of its assets to Mitsubishi Chemical Performance Polymers, Inc. on January 31, 2020, today announced that the Companys Board of Directors approved a special cash distribution of $0.18 per share at its April 3, 2020 meeting.
  • The cash distribution is payable on April 23, 2020 to shareholders of record as of April 16, 2020.
  • EKIMAS Corporation, formerly AdvanSource Biomaterials Corporation (the Company), sold substantially all of its assets to Mitsubishi Chemical Performance Polymers, Inc. on January 31, 2020 (the Closing Date).
  • As a result, the Company ceased operating as a manufacturer and seller of advanced polymers.

K Health and LSU Partner for Louisiana Statewide COVID-19 Relief

Monday, April 6, 2020 - 6:00pm

Dr. Rebekah Gee, CEO of LSU Health Care Services Division says, In this time of uncertainty, LSU is here for you.

Key Points: 
  • Dr. Rebekah Gee, CEO of LSU Health Care Services Division says, In this time of uncertainty, LSU is here for you.
  • LSU and K Health are proud to offer free services to the public and access to a physician during this critical time.
  • Partnering with K Health brings some relief to the community via telemedicine to help the growing numbers of people deeply affected by COVID-19.
  • K Health is a digital health company that offers free personalized healthcare.

Ultraviolet LEDs see Rising Demand as Coronavirus Spurs Increased Interest in Disinfectant Technologies - ResearchAndMarkets.com

Monday, April 6, 2020 - 5:26pm

ResearchAndMarkets.com sees UV LEDs as a key area experiencing growth due to the coronavirus pandemic.

Key Points: 
  • ResearchAndMarkets.com sees UV LEDs as a key area experiencing growth due to the coronavirus pandemic.
  • Concerns over the spread of coronavirus has led to increased interest in ultraviolet LED technology which can be used to kill influenza germs and sterilize surfaces, leading companies like GermFalcon and Viosys to benefit from this opportunity.
  • Viosys reported that inquiries for its VioLED UV LED range of products have increased by five times over the previous month due to concerns over the spread of COVID-19.
  • Since the outbreak, CleanSlate UV, a company that makes devices to clean medical devices and phones with UV light, has received inquiries by companies spanning industries from manufacturing to education.

Xerox and Vortran Medical Partnering to Mass Produce Disposable Ventilators

Monday, April 6, 2020 - 5:30pm

Together, Xerox and Vortran could produce as many as 1 million ventilators in the coming months.

Key Points: 
  • Together, Xerox and Vortran could produce as many as 1 million ventilators in the coming months.
  • Our smartest minds met (virtually) with Vortrans smartest minds and figured out how to mass produce this critical technology, said John Visentin, vice chairman and chief executive officer, Xerox.
  • VORTRAN Medical Technology has been providing medical device excellence since 1983.
  • Xerox is a trademark of Xerox Corporation in the United States and/or other countries.

Learning from Times of Uncertainty: HR’s Critical Role in Business Continuity

Monday, April 6, 2020 - 5:00pm

Human resources (HR) is a critical business partner during times of uncertainty, as HR is one of the first places employees look to for support and direction in times of crisis.

Key Points: 
  • Human resources (HR) is a critical business partner during times of uncertainty, as HR is one of the first places employees look to for support and direction in times of crisis.
  • Its vital that HR plays a proactive role in business continuity.
  • Kronos Incorporated will present the educational webinar Learning from Times of Uncertainty: Human Resources Critical Role in Business Continuity in collaboration with Ankura, a leading collaborative consulting group with deep domain expertise in business continuity planning.
  • With nearly three decades of experience in information technology, he is a certified business continuity professional, helping organizations enable and optimize business operations.